Hemogenyx Pharmaceuticals PLC CDX Development Agreement Extension (6974O)
2020年6月2日 - 7:29PM
RNSを含む英国規制内ニュース (英語)
TIDMHEMO
RNS Number : 6974O
Hemogenyx Pharmaceuticals PLC
02 June 2020
Hemogenyx Pharmaceuticals plc
(the "Company")
CDX Development Agreement Extension
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for deadly blood
diseases, announces that it has extended its development agreement
( " Agreement " ) with a leading global pharmaceutical company
("GlobalCo") engaged in the research, development, manufacture and
marketing of pharmaceutical products.
On 14 May 2018, the Company announced a collaboration with
GlobalCo to work on the Company's CDX antibody product candidate.
Under the Agreement, which stipulates that GlobalCo's identity
remain anonymous for the time being, the Company is receiving, free
of charge, technical support, access to advanced methods of
discovering, developing and engineering antibodies, and certain
intellectual property necessary for the successful preclinical
development of the Company's lead candidate bi-specific CDX
antibody. This collaboration complements the Company's own
development work that is currently being undertaken.
As a result of the global crisis caused by the COVID-19
pandemic, the Company and GlobalCo have agreed to extend the
Agreement by three months in order to properly complete the work
required by both parties thereunder.
The Company's CEO, Dr Vladislav Sandler, commented, "We are very
pleased with the substantial work that has been done so far with
our GlobalCo partner on our CDX antibody product candidate, and
look forward to our continued collaboration and the successful
completion of this important work."
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
US Media enquiries Tel: +1 (323) 646-3249
Lowell Goodman lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its US operating
subsidiaries, Hemogenyx LLC and Immugenyx LLC, located at its
state-of-the-art research facility in New York City and a Belgian
subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx Pharmaceuticals plc is a pre-clinical stage
biopharmaceutical group developing new medicines and treatments to
treat blood and autoimmune disease and to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases. The
Company is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an
engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx Pharmaceutical
plc's technology has the potential to enable many more patients
suffering from devastating blood diseases such as leukemia and
lymphoma, as well as severe autoimmune diseases such as multiple
sclerosis, aplastic anemia and systemic lupus erythematosus
(Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBGGDLUDGDGGD
(END) Dow Jones Newswires
June 02, 2020 06:29 ET (10:29 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 6 2024 まで 7 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 7 2023 まで 7 2024